GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NexGel Inc (NAS:NXGL) » Definitions » Insider Ownership

NexGel (NexGel) Insider Ownership : 19.80 % (As of Jun. 10, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NexGel Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NexGel's insider ownership is 19.80%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NexGel's Institutional Ownership is 0.57%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NexGel's Float Percentage Of Total Shares Outstanding is 75.11%.


NexGel Insider Ownership Historical Data

The historical data trend for NexGel's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexGel Insider Ownership Chart

NexGel Historical Data

The historical data trend for NexGel can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Insider Ownership 20.72 20.95 20.87 20.87 20.94 20.94 20.85 21.47 19.80 19.80

NexGel Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


NexGel (NexGel) Business Description

Traded in Other Exchanges
N/A
Address
2150 Cabot Boulevard West, Suite B, Langhorne, PA, USA, 19047
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies. The company recognizes revenue from contract manufacturing.
Executives
Steven Mark Glassman director 99 LEWIS POINT ROAD, FAIR HAVEN NJ 07704
Nachum Stein director QUADRAX CORP, 618 MAIN ST PO BOX 1001, WEST WARWICK RI 02893
Scott Robert Henry director 34A ATLANTIC AVE., COHASSET MA 02025
David Stefansky director 850 THIRD AVENUE, SUITE 1801, NEW YORK NY 10022
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Yaakov Spinrad director 3450 OAKTON ST, SKOKIE IL 60076
Drapczuk Adam E Iii officer: Chief Financial Officer 6 OAKMONT TERRACE, EAST WINDSOR NJ 08520
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Bezalel Partners Llc 10 percent owner C/O KRIEGER & PRAGER LLP, 39 BROADWAY, STE 920, NEW YORK NY 10006
Adam R. Levy officer: CEO and President 2 AVENUE OF TWO RIVER SOUTH, RUMSON NJ 07760
David Ian Johnson director, officer: Chief Executive Officer C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Adynxx, Inc. 10 percent owner 100 PINE ST., STE. 500, SAN FRANCISCO CA 94111